Hims & Hers down as FDA advisors snub first peptide

FDA advisory committee rejected Hims & Hers' peptide candidate, sending the telemedicine company's stock down. The negative decision signals regulatory hurdles for telehealth players moving into weight-loss and metabolic drug delivery.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.